1. Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience
- Author
-
Vincenzi, B, Nannini, M, Fumagalli, E, Bronte, G, Frezza, Am, De Lisi, D, Spalato Ceruso, M, Santini, D, Badalamenti, G, Pantaleo, Ma, Russo, A, Dei Tos AP, Casali, P, and Tonini, G
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Second line treatment ,GiST ,Sunitinib ,business.industry ,Imatinib ,Metastatic gist ,Surgery ,Exon ,Internal medicine ,Dose escalation ,medicine ,Retrospective analysis ,business ,neoplasms ,medicine.drug - Abstract
10515 Background: Data from metastatic GIST patients harbouring exon 11 mutation who received a second line treatment with sunitinib or imatinib dose escalation were retrospectively analysed to compare survival. Methods: 123 exon 11 mutated advanced GIST patients were included. All patients progressed on imatinib 400 mg/die and received, on discretion of physician, a second line treatment with either imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 weeks of or 37.5 mg/day continuous daily dose). The type of exon 11 mutation was recorded (deletion versus others) and correlated with survival and response according to RECIST or CHOI criteria Results: 79 patients (64%) received a second line treatment with imatinib, 44 (36%) sunitinib. For 94 patients the exact mutation was available: exon 11 mutation was represented by a deletion in 42 cases (45%), by other gene aberrations in 52 (55%). Median follow-up was 61 months. The median time to progression (TTP) in patients receiving sunitinib and imatinib...
- Published
- 2014